Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

This Trial is Conducted Globally. The Aim of This Trial is to Investigate Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis

NCT02970942 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02970942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02970942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
This Trial is Conducted Globally. The Aim of This Trial is to Investigate Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2016
Completion date
March 19, 2020
Enrollment
320 (actual)
Sites
158

Conditions

As the registry lists them; a condition with its own page is linked.

hepatobiliary disorders, non-alcoholic steatohepatitis